Parameter | Placebo (n = 65) | AZL-M 40 mg (n = 132) | AZL-M 80 mg (n = 130) | Total (N = 327) |
---|---|---|---|---|
Age, mean (SD), yearsa | 58.8 (10.2) | 59.8 (10.8) | 58.3 (11.6) | 59.0 (11.0) |
< 65 years, n (%) | 44 (67.7) | 82 (62.1) | 89 (68.5) | 215 (65.7) |
≥ 65 years, n (%) | 21 (32.3) | 50 (37.9) | 41 (31.5) | 112 (34.3) |
Sex, n (%) | ||||
Male | 51 (78.5) | 95 (72.0) | 93 (71.5) | 239 (73.1) |
Female | 14 (21.5) | 37 (28.0) | 37 (28.5) | 88 (26.9) |
Height, mean (SD), cm | 166.1 (8.4) | 164.8 (9.1) | 165.6 (8.0) | 165.4 (8.5) |
Weight, mean (SD), kgb | 70.9 (9.9) | 71.0 (12.6) | 70.3 (13.1) | 70.7 (12.3) |
BMI, mean (SD), kg/m2c | 25.64 (2.7) | 26.02 (3.3) | 25.50 (3.5) | 25.74 (3.2) |
eGFR, mean (SD), mL/min/1.73 m2 | 85.7 (14.8) | 87.4 (18.4) | 88.7 (18.4) | 87.6 (17.7) |
Diabetes status, n (%) | ||||
Yes | 4 (6.2) | 21 (15.9) | 13 (10.0) | 38 (11.6) |
No | 61 (93.8) | 111 (84.1) | 117 (90.0) | 289 (88.4) |
Concomitant medication, n (%)d | ||||
Medication continued into double-blind treatment period | 26 (40.0) | 50 (37.9) | 57 (43.8) | 133 (40.7) |
Initiated use during double-blind treatment period | 43 (66.2) | 87 (65.9) | 89 (68.5) | 219 (67.0) |
Smoking classification, n (%) | ||||
Never smoked | 29 (44.6) | 71 (53.8) | 65 (50.0) | 165 (50.5) |
Ex-smoker | 24 (36.9) | 39 (29.5) | 39 (30.0) | 102 (31.2) |
Current smoker | 12 (18.5) | 22 (16.7) | 26 (20.0) | 60 (18.3) |
scSBP, mean (SD), mmHge | 158.8 (7.4) | 158.9 (8.0) | 160.1 (7.4) | 159.4 (7.6) |
scDBP, mean (SD), mmHgf | 94.3 (11.0) | 93.1 (9.6) | 93.2 (9.5) | 93.4 (9.8) |